Pancreatic Cancer

FDA Approves New Pancreatic Cancer Drug, Ending Decades of Treatment Dilemma

Core Summary The U.S. Food and Drug Administration has officially approved an innovative drug for pancreatic cancer treatment, considered the most important therapeutic breakthrough in this field in decades. Pancreatic cancer, known as the “king of cancers” due to its high mortality rate and limited treatment options, now offers new survival hope for tens of thousands of patients with this new drug approval. Event Details According to The Wall Street Journal, this FDA approval marks a major milestone in pancreatic cancer treatment. Pancreatic cancer is the third leading cause of cancer death in the United States, with a five-year survival rate of only about 12%, far lower than most other common cancers. For a long time, treatment options have been largely limited to chemotherapy and surgery, with most patients diagnosed at advanced stages. ...

FDA Approves Early Access to Breakthrough Pancreatic Cancer Drug, First RAS Inhibitor Shows Promise

The FDA approves expanded access to daraxonrasib, the first RAS-targeting inhibitor for pancreatic cancer, which has shown promise in extending survival for metastatic patients in clinical trials.

FDA Expands Access to Promising Pancreatic Cancer Drug daraxonrasib

The FDA has granted expanded access to Revolution Medicines’ targeted pancreatic cancer drug daraxonrasib, opening a pathway for more patients to receive a therapy that has shown promising results in clinical trials.

FDA Grants Expanded Early Access to Breakthrough Pancreatic Cancer Drug Daraxonrasib

The U.S. FDA approves expanded access to daraxonrasib, a breakthrough targeted therapy for previously treated metastatic pancreatic ductal adenocarcinoma, offering new hope for patients with one of the deadliest cancers.

FDA Grants Early Access to Breakthrough Pancreatic Cancer Drug

The US FDA approves expanded access to daraxonrasib, an innovative pancreatic cancer drug, offering new hope for patients facing one of the deadliest forms of cancer.

FDA Grants Early Access to Promising Pancreatic Cancer Drug Daraxonrasib

The FDA approves an expanded access program for daraxonrasib, an innovative pancreatic cancer drug that showed promising results in clinical trials, offering new hope for patients with one of the most challenging cancers.

FDA Grants Expanded Early Access to Pancreatic Cancer Drug Daraxonrasib

The U.S. FDA approves expanded early access for the experimental pancreatic cancer drug daraxonrasib, offering new hope for late-stage patients.

AI System Detects Pancreatic Cancer 16 Months Before Diagnosis, Nearly Double Expert Detection Rate

A Mayo Clinic-developed AI system called REDMOD can identify pancreatic cancer signatures from CT scans an average of 16 months before clinical diagnosis, with a detection rate nearly double that of human specialists.

Mayo Clinic AI Breakthrough: Detects Pancreatic Cancer Up to 3 Years Before Diagnosis

Mayo Clinic announced a breakthrough research finding: its AI model can detect invisible tissue changes of pancreatic cancer up to 3 years before diagnosis, demonstrating unprecedented early detection capabilities in a landmark validation study.

Mayo Clinic AI Detects Pancreatic Cancer Up to 3 Years Before Diagnosis in Landmark Study

Mayo Clinic publishes a landmark validation study showing its AI model can detect early tissue changes of pancreatic cancer in routine CT scans, identifying the disease years before traditional diagnosis.